Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement...
Business Wire
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of -16.13% and -38.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash...
Business Wire
Pulse Biosciences to Present at Canaccord Genuitys 46th Annual Growth Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Pulse Biosciences Management is...
Business Wire
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026. We are very pleased by...
Business Wire
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026...
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement...
Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock...
Business Wire
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences Management is...
Business Wire